The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...